First experience of implantation of a new-generation bioresorbable stent in a young patient with coronary artery disease: a case report

Implantation of a drug-eluting stent into the area of hemodynamically significant coronary artery lesion is a generally accepted and widespread method of coronary artery disease (CAD) treatment. However, rigid metallic frame in artery is associated with disrupted vascular biomechanics and neointimal proliferation in response to foreign material. These processes can lead to restenosis and/or late thrombosis of the implanted stent and, as a consequence, to the recurrence of CAD symptoms, as well as to adverse cardiovascular events. One of the options for solving the above problems is the implantation of bioresorbable stents. This technique already has an evidence base and is increasingly being introduced into routine clinical practice in certain groups of patients. The article presents a case of successful balloon angioplasty and stenting of the right coronary artery with a new-generation bioresorbable stent in a young patient with CAD.

1. Wang Y, Zhan J, Bian W et al. Local hemodynamic analysis after coronary stent implantation based on Euler-Lagrange method. J Biol Phys. 2021 Jun;47(2):143-170. doi: 10.1007/s10867-021-09571-y.

2. Chi G, AlKhalfan F, Lee JJ et al. Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial. Front Cardiovasc Med. 2024 Jan 8;10:1269011. doi: 10.3389/fcvm.2023.1269011.

3. Zong J, He Q, Liu Y et al. Advances in the development of biodegradable coronary stents: A translational perspective. Mater Today Bio. 2022 Jul 19;16:100368. doi: 10.1016/j.mtbio.2022.100368.

4. Suwannasom P, Sotomi Y, Ishibashi Y et al. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. JACC Cardiovasc Interv. 2016 Jun 27;9(12):1231-1242. doi: 10.1016/j.jcin.2016.03.027.

5. Stone GW, Kereiakes DJ, Gori T et al. 5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique. J Am Coll Cardiol. 2023 Jul 18;82(3):183-195. doi: 10.1016/j.jacc.2023.05.003.

6. Seth A, Onuma Y, Costa R et al. First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial. EuroIntervention. 2017 Jul 20;13(4):415-423. doi: 10.4244/EIJ-D-17-00306.

7. Abizaid A, Kedev S, Ali RBM et al. Imaging and 2-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold: The MeRes-1 extend trial. Catheter Cardiovasc Interv. 2021 Nov 15;98(6):1102-1110. doi: 10.1002/ccd.29396.

8. Abizaid A, Kedev S et al. Imaging and 2-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold: The MeRes-1 extend trial. Catheter Cardiovasc Interv. 2021 Nov 15;98(6):1102-1110. doi: 10.1002/ccd.29396.